Peptilogics is at the forefront of peptide therapeutics, leveraging advanced technologies to revolutionize drug discovery for serious diseases. The company utilizes a proprietary AI platform, Nautilus™, which enables in silico predictive peptide design. This platform combines novel AI algorithms with supercomputing capabilities to explore previously untapped chemical spaces, allowing for the efficient design of peptides with optimized properties such as binding affinity, selectivity, and safety. By integrating extensive datasets from chemistry, biology, and pharmacology, Peptilogics can rapidly synthesize and validate peptides, significantly accelerating the drug discovery process.

The company’s lead candidate, PLG0206, exemplifies its innovative approach to peptide therapeutics. Designed to combat periprosthetic joint infections (PJI), PLG0206 has shown promising in vitro and nonclinical activity, along with a favorable safety profile in early clinical trials. This investigational peptide targets multi-drug resistant bacteria through a unique mechanism that disrupts bacterial cell membranes, addressing a critical need in the treatment of infections that often evade conventional antibiotics. Peptilogics is committed to advancing its pipeline of peptide therapeutics across various disease areas, focusing on conditions with high unmet medical needs and utilizing its AI-driven platform to enhance the efficiency and effectiveness of drug development.

United States

Peptilogics was founded in 2013 to advance novel peptide therapeutics and harness the power of a design-based approach to drug discovery. Our approach bridges untapped chemical space to engineer peptides to treat some of the most challenging diseases. Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics through their computational platform.

Peptilogics

Company Details